Second, indirect inhibitors of STAT3 have demonstrated some side effects in phase I/II clinical trials, such as neurological complications and bone marrow suppression, etc. Due to the low immunity and poor nutritional status of cancer patients, there is a need to further evaluate the safety of JAK and IL-6 inhibitors. The gene discussed is IL6; the disease is cancer.